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Abstract
Background: Much attention has been recently focused on the role of cancer stem cells (CSCs)
in the initiation and progression of solid malignancies. Since CSCs are able to proliferate and self-
renew extensively, thus sustaining tumor growth, the identification of CSCs through their antigenic
profile might have relevant clinical implications. In this context, CD133 antigen has proved to be a
marker of tumor cells with stemness features in several human malignancies.
The aim of the study was to investigate the clinical role of the immunohistochemically assessed
expression of CD133 in a large single Institution series of ovarian cancer patients.
Methods: The study included 160 cases admitted to the Gynecologic Oncology Unit, Catholic
University of Campobasso and Rome. CD133 antigen was identified by the monoclonal mouse anti-
CD133-1 antibody (clone CD133 Miltenyi biotec).
Results: In the overall series CD133 positive tumor cells were observed in 50/160 (31.2%) cases.
A diffuse cytoplasmic pattern was identified in 30/50 (60.0%), while an apical cytoplasmic pattern was
found in 20/50 (40.0%) of CD133 positive tumors.
As of September 2008, the median follow up was 37 months (range: 2–112). During the follow up
period, progression and death of disease were observed in 123 (76.9%), and 88 (55.0%) cases,
respectively. There was no difference in TTP between cases with negative (median TTP = 23
months) versus positive CD133 expression (median TTP = 24 months) (p value = 0.3). Similar
results were obtained for OS. When considering the TTP and OS curves according to the pattern
of CD133 expression, a trend to a worse prognosis for cases with diffuse cytoplasmic versus the
apical cytoplasmic pattern was documented, although the statistical significance was not reached.
Conclusion: The immunohistochemical assessment of CD133 expression seems not to provide
additional prognostic information in ovarian cancer patients. The role of the different pattern of
CD133 immunoreaction deserves further investigation in a larger series.
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Background
Increasing attention is currently focused on the role of
cancer stem cells (CSCs) in the initiation and progression
of leukemias and solid malignancies [1]. In particular, in
the CSC model only a small proportion of tumor cells are
proposed to be able to proliferate and self-renew exten-
sively, thus sustaining tumor growth, while the bulk of
cell populations proceed to differentiate into heterogene-
ous clones that become the phenotypic signature of the
tumor [1]. The existence of CSCs was first demonstrated
by transplantation of a small population of harvested leu-
kaemia cells from patients into immunodeficient mice,
which then developed the same malignancy [2]. Since
then, CSCs have been described in several human tumors
including breast, gastrointestinal, lung, prostate, brain,
and melanoma on the basis of their clonogenic efficiency
in vitro and ultimately tumorigenicity in vivo [3-9]. The
identification and characterization of CSCs might have
unpredictably huge clinical implications: for instance, it is
has been shown that CSCs might survive chemo- as well
as radiotherapy [10-14], due to the preferential expression
of resistance molecules or activation of specific signaling
pathways. It is therefore intuitively conceivable that only
the eradication of CSCs or, alternatively, the induction of
CSCs differentiation into cells lacking self-renewal poten-
tial can lead to an effective cancer cure. CSCs in specific
tumor types are associated with elevated expression of the
stem cell surface marker CD133 [15], which can be ulti-
mately used for the identification as well as purification
and enrichment of CSCs population [4-7], by means of a
specific antibody directed against the AC133 and AC141
epitopes. CD133 (formely known as AC133) is a 5-trans-
membrane cell surface glycoprotein located in plasma
membrane protrusions where it could act as a regulator of
lipid composition, cell polarity and migration [16].
In transplantation experiments CD133+ glioblastoma as
well as colon cancer cells successfully induced tumors in
immunodeficient mice [4-7]. Moreover, CD133 antigen
expression has been identified in various types of solid
tumours [5,9,10,16-18], and documented to be associated
with patients' response to treatment and clinical outcome;
in particular, CD133+ glioma cells were shown to exhibit
resistance to radiation [17], and chemotherapy [18].
Moreover, elevated blood levels of CD133 mRNA have
been shown to be associated with poor overall survival in
patients with bone metastatic disease [19], and with a
higher risk of recurrence in colon cancer [20] Some
authors have also addressed the clinical role of the immu-
nohistochemically assessed CD133 expression in gliomas
as well as pancreatic and hepatocellular carcinomas [21-
24]: with the limits of some methodological differences
(type of antibody, definition of the cut-off values of
CD133 positivity, etc), the unfavourable prognostic role
of high CD133 expression has been recognized in most of
the studies [21-23]. As far as ovarian cancer is concerned,
isolation and characterization of cellular clones with clo-
nogenic potential in vitro and tumorigenicity in vivo even
after serial transplantation in mice, have been recently
documented [25]. We recently showed that that CD133
antigen represents a useful molecule in order to select and
enrich the population of ovarian tumor cells expressing a
higher clonogenic efficiency and proliferative potential
[26]. Moreover, CD133+ Ovarian cancer cell lines have
been very recently shown to exhibit enhanced resistance
to platinum-based therapy, and to form more aggressive
tumor xenografts at a lower inoculum than their CD133-
progeny [27,28].
To the best of our knowledge, no data has been reported
until now about the potential clinical role of the immuno-
histochemically assessed expression of CD133 and its in
ovarian cancer in a large, single Institution series of pri-
mary untreated ovarian cancer patients.
Methods
Patient population
The study included 160 ovarian cancer patients admitted
to the Gynecologic Oncology Unit, Catholic University of
Campobasso and Rome between May 1999 and January
2006. Although this study only included a retrospective
collection of archival data, the protocol was submitted to
our Institutional Review Board, and approved for the use
of patients' clinical information. Clinico-pathological
characteristics of the overall series are summarized in
Table 1. Forty-seven (29.4%) patients were >65 years old
(median age = 58 years, range:24–83). One-hundred
nineteen cases (74.4%) were stage III, and 21 (13.1%)
cases were stage IV disease. Serous histotype was docu-
mented in the vast majority (n = 115, 71.9%) of cases. All
patients underwent primary surgical effort at the Catholic
University of Campobasso-Rome by only two surgical
teams, which share the same surgical approach, and are
able to obtain the same results in terms of percentage of
optimal cytoreduction at primary surgery. Maximal surgi-
cal effort has been attempted in all patients resulting in
optimal debulking (apparently absent residual tumor) in
52 (32.5%) cases, which underwent surgical removal of
tumour masses, along with total abdominal hysterec-
tomy, adnexectomy, radical omentectomy, appendec-
tomy, multiple biopsies, and additional surgery
(intestinal resections, diaphragm stripping) when
required.
Suboptimal cytoreduction was achieved in 40 (25.0%)
cases, while 68 cases (42.5%) were judged to be unresect-
able at first surgery because of extensive peritoneal bulky
carcinomatosis, agglutinated bowel/mesentery and infil-
tration of the upper gastrointestinal tract and/or the major
vessels, and were submitted only to multiple biopsies. AllBMC Cancer 2009, 9:221 http://www.biomedcentral.com/1471-2407/9/221
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patients received platinum-based chemotherapy (75–100
mg/m2 for cisplatin, AUC = 5 for carboplatin, per cycle),
plus paclitaxel (135–175 mg/m2 for each cycle). As far as
patients undergoing only exploratory laparotomy are con-
cerned, they received 3–4 cycles of chemotherapy before
attempting a second cytoreductive surgery, unless they
showed clinical progression during treatment. In all
patients response to chemotherapy was assessed accord-
ing to WHO criteria [29]. For the purposes of data analy-
sis, complete and partial response were grouped together
and classifies as "response to treatment", while cases with
stabilization of disease or progression were considered as
"no response to treatment".
Immunohistochemistry
Pre-treatment tumor tissues biopsies were obtained at first
surgery in all cases. Immunostaining was performed as
previously described [26]. Briefly, 3 mm formalin fixed,
paraffin-embedded slides from cancer tissue sections,
were deparaffinized in xylene and rehydrated convention-
ally; the endogenous peroxidase was blocked with 3%
H2O2 for 5 min. To reduce non specific binding the sec-
tions were incubated with 20% normal goat serum for 30
min, at room temperature. Cells expressing CD133 anti-
gen were identified after overnight incubation at 4°C by
using the monoclonal mouse anti-CD133-1 antibody
(clone CD133 Miltenyi biotec) (1:50 dilution) which has
been shown to provide the most sensitive results with the
lowest background, and has been previously used to iden-
tify cells with stemness features in other human malig-
nancies [24,30]. CD133 detection was performed by
using anti-mouse EnVision System-HRP (DakoCytoma-
tion, Carpinteria, CA, USA), for 30 min. at room temper-
ature. Diaminobenzidine was used as a chromogen (DAB
substrate System, DAKO). Immunohistochemical stained
slides were reviewed by two investigators (GZ, EM) inde-
pendent from one another, and blinded to clinical data.
CD133 stained cells were counted in 10 random and non-
overlapping fields at high magnification (400×), and the
results were expressed as the percentage of total number of
nuclei counted in the same fields [22]. For analysis of sur-
vival patients were divided into negative (% CD133+
tumor cells = 0) versus positive (% CD133- tumor cells>0)
CD133 expression.
Table 1: Clinico-pathological characteristics of the overall series, and percentage of cases with positive CD133 expression
Characteristics No. pts (%) No. (%) of cases with positive CD133 expression p valuea
All cases 160 50 (31.2)
Age (yrs)
<65 113 (70.6) 36 (31.9)
³ 65 47 (29.4) 14 (29.8) 0.8
FIGO Stage
I-II 20 (12.5) 6 (30.0)
III 119 (74.4) 39 (32.8)
IV 21 (13.1) 5 (23.8) 0.7
Grade
G1-2 28 (17.4) 7 (25.0)
G3 107 (66.8) 34 (31.8) 0.5
n.a. 35 (21.8)
Histotype
Serous 115 (71.9) 33 (28.7)
Other 45 (28.1) 17 (40.5) 0.2
Residual tumor
Absent 52 (32.5) 19 (36.5)
Suboptimal 40 (25.0) 8 (20.0)
Exploratory laparotomy 68 (42.5) 23 (33.8) 0.2
Response to treatment
Yes 130 (81.2) 43 (33.1)
No 30 (18.8) 7 (23.3) 0.3
acalculated by Fisher's exact test for proportion or X2 test
n.a. = not availableBMC Cancer 2009, 9:221 http://www.biomedcentral.com/1471-2407/9/221
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Statistical analysis
X2 test or Fisher's exact test for proportion were used to
analyze the distribution of cases with positive CD133
expression according to clinico-pathological parameters.
Time to progression (TTP) and overall survival (OS) were
calculated from the date of diagnosis to the date of pro-
gression/death or date last seen. Medians and life tables
were computed using the product-limit estimate by the
Kaplan and Meier method [31], and the log-rank test was
employed to assess the statistical significance [32]. Statis-
tical analysis was carried out using SOLO (BMDP Statisti-
cal Software, Los Angeles, CA). Multivariate analysis
assessing the clinical role of CD133 expression matched
with other clinico-pathological characteristics was per-
formed by Cox's proportional hazards model [33].
Results
CD133 expression protein in primary ovarian cancer
Figure 1 shows representative examples of CD133 antigen
expression in primary ovarian cancer: Immunoreaction
appeared to be present as a diffuse staining of cytoplasm
(diffuse cytoplasmic pattern) of tumor cells forming solidly
arranged tumors or at the apical/endoluminal surface
(apical cytoplasmic pattern) of tumor cells surrounding a
lumen.
The distribution of the percentages of CD133 stained cells
is shown in Figure 2: in the overall series CD133 positively
stained tumor cells were observed in 50/160 (31.2%)
cases, and the mean +SE values of proportion of CD133
positive cells was = 0.48 +0.08 (range:0–4.93). Moreover,
the  diffuse cytoplasmic pattern was identified in 30/50
(60.0%), while the apical cytoplasmic pattern was found in
20/50 (40.0%) of CD133 positive tumors. There was no
difference in the distribution of cases with positive CD133
expression according to any of the clinico-pathological
parameters examined, including response to chemother-
apy (Table 1).
As of September 2008, the median follow up was 37
months (range: 2–112). During the follow up period, pro-
gression and death of disease were observed in 123
(76.9%), and 88 (55.0%) cases, respectively. Given the
intertumor variability, the absence of a defined scoring
system, and the need to minimize any source of bias
related to the use of a specific cut off value, the possible
clinical role of CD133 expression in ovarian cancer was
examined by Cox proportional hazard model using the
percentage of Cd133 positive tumor cells as a continuous
value, and by Kaplan and Meier analysis.
No association between the percentage values of posi-
tively CD133 positive immunostained tumor cells
expressed as continuous value and the relative risk of pro-
gression (X2 = 2.96, p value = 0.09), or death of disease (X2
= 0.10, p value = 0.75) was found (data not shown).
Figure 3 shows the TTP and OS curves according to CD133
expression status: there was no difference in TTP between
cases with negative (median TTP = 23 months) versus pos-
itive CD133 expression (median TTP = 24 months) (p
value = 0.3). Similar results were obtained for OS: cases
with negative CD133 expression experience a median OS
of 52 months versus a median OS of 49 months in posi-
tive CD133 expression (p value = 0.6).
There was no difference in the clinical outcome according
to CD133 status in patients achieving primary optimal
cytoreduction (p values for TTP and OS = 0.51 and 0.58,
respectively), or in patients considered to be unresectable
at primary laparotomy (p values for TTP and OS = 0.50
and 0.82, respectively) (data not shown). Interestingly
enough, when considering the TTP and OS curves accord-
ing to the pattern of CD133 expression, a trend to a better
prognosis for cases with apical cytoplasmic versus diffuse
CD133 immunoreaction in primary ovarian cancer Figure 1
CD133 immunoreaction in primary ovarian cancer. 
A) Negative control; B) Representative example of CD133 
positive immunoreaction in the cytoplasm of solidly arranged 
tumor cells; C, D) Representative examples of CD133 posi-
tive staining at the apical/endoluminal portion of tumor cells. 
Magnification = 100× (A, B, C); 200× (D).
A B
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Distribution of the values of the percentage of CD133 positively immunostained tumor cells Figure 2
Distribution of the values of the percentage of CD133 positively immunostained tumor cells.
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cytoplasmic pattern was documented, although the statisti-
cal significance was not reached (Figure 4). We also tried
to examine patients' prognosis after grouping cases with
negative and apical cytoplasmic pattern versus cases with
only diffuse cytoplasmic pattern. Indeed, we could not doc-
ument any difference in terms of TTP (p value = 0.35) and
OS (p value = 0.48) between these two groups.
In multivariate analysis of TTP and OS, advanced stage,
suboptimal residual tumor at primary surgery, and
response to primary treatment were found to be associ-
ated with a high risk of progression, and/or death of dis-
ease (Table 2).
There was no difference in the clinical outcome of cases
with negative versus positive CD133 expression when
analyzing the subgroup of platinum resistant (TTP, p
value = 0.80; OS, p value = 0.77), and platinum sensitive
patients (TTP, p value = 0.85; OS, p value = 0.11) (data
not shown).
Discussion
This is the first study analyzing the immunohistochemi-
cally assessed expression of CD133 antigen in a large, sin-
gle Institution series of primary ovarian carcinomas.
CD133 immunoreaction appeared to be expressed at the
apical/endoluminal surface of tumor cells forming a
lumen, as reported in a small series of primary ovarian
carcinomas [27], as well as in pancreatic [22,24], and gas-
tric carcinoma [34], while it was mainly localized in the
cytoplasm of cells forming solidly arranged tumors.
CD133 positivity in the current series was in the range
reported in other human solid tumors by studies employ-
ing immunohistochemical assays [12,22], confirming
that only a very small proportion of tumor cells with
stemness features exist within the tumor bulk.
However, the current results differ from our previous find-
ings in that higher percentage of CD133 positive tumor
cells were documented in a small series of primary ovarian
carcinomas analyzed by fluorescence activated cell sorting
(FACS) [26]: among the possible explanations of this dis-
crepancy, the potential effects of mechanical and enzy-
matic procedures used in the preparation of cell
suspension for FACS analysis should be taken into
account: indeed, the disruption of the cellular microenvi-
ronment is likely to influence surface membrane antigens,
although the extent of this phenomenon has been not yet
addressed. In this context, a more in depth analysis of the
correlation between immunohistochemically and FACS
assessed CD133 positive tumor cells would be of utmost
importance.
Given the strong rationale linking CD133 expression to
more aggressive cellular behaviour, including resistance to
chemotherapy and radiotherapy, several studies have
Time to progression (A) and overall survival (B) curves in ovarian cancer patients according to the pattern of CD133 expres- sion Figure 4
Time to progression (A) and overall survival (B) curves in ovarian cancer patients according to the pattern of 
CD133 expression.
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addressed its correlation with clinico-pathological charac-
teristics of cancer patients: in particular, a direct correla-
tion between CD133 expression and advanced stage of
disease as well as poor grade of differentiation has been
shown in hepatocellular carcinoma [23]. Moreover, in
pancreatic cancer the percentage of CD133 positivity cor-
relates with metastatic lymph node involvement and also
with VEGF-C expression and microvessel density [22]. As
far as clinical outcome is concerned, elevated expression
of CD133 has been reported to identify, even in multivar-
iate analysis, poor prognosis patients bearing hepatocellu-
lar, pancreatic and glioma tumors [21,23].
We failed to find any association between CD133 expres-
sion and any of the clinico-pathological features exam-
ined. Moreover, we could not document any difference in
terms of time to progression and overall survival accord-
ing to CD133 status. These results are unlikely related to
the potential bias inherent in the use of an arbitrary cut-
off point, since clinical outcome was also studied utilizing
the percentage of CD133 positive tumor cells as a contin-
uous value; moreover, all patients were diagnosed,
treated, and followed up at the same Institution, thus
reducing the bias related to the differences in the extent of
surgical cytoreduction or general management of this neo-
plasia. Finally, the analysis of TTP according to CD133
status minimizes the clinical impact of post-relapse chem-
otherapeutic regimens.
The absence of any correlation between CD133 expres-
sion and clinical outcome remains to be clarified: doubts
about the limitations in the use of antibodies recognizing
the AC133 and AC141 epitopes have been cast: indeed,
discordant expression of the two epitopes has been docu-
mented, and it has been also demonstrated that both
AC133 and AC141 can be absent despite the presence of
CD133 protein [35]. In addition, it cannot be excluded
that the role of CD133 as a marker of CSCs may differ
according to tumor type: for instance, in gliomas and
glioblastomas, CD133 expression has been shown not to
be an absolute requirement for tumor initiation and pro-
gression [36,37], thus leading to hypothesize that it could
just characterize populations with enhanced proliferative
potential. In this context, it has to be taken into account,
as emphasized by Kelly et al. [38], that the ability of
CD133 positive cells to form tumors in vivo is also condi-
tioned by the interaction with host microenvironment
and immune system, an issue which is often ignored.
Therefore, the possibility that CD133 does not represent a
marker for CSCs, but rather characterizes tumor cells more
effectively able to grow in other species, cannot, in princi-
ple, be ruled out. Finally, the role of the different pattern
Table 2: Multivariate analysis of clinico-pathological parameters and CD133 status as prognostic factors for TTP and OS in primary 
ovarian cancer patients
Variable Multivariate for TTP Multivariate for OS
c2 P value c2 p value
Age (yrs)
£  65
>65 2.9 0.08 2.1 0.14
Stage
I-II
III-IV 1.7 0.2 4.1 0.04
Histotype
Serous
Other 0.4 0.5 0.8 0.4
Residual tumor
Absent/suboptimal
Exploratory laparotomy 18.1 0.0001 15.2 0.0001
Response to treatment
No
Yes 11.7 0.0006 3.4 0.06
CD133 status
Negative
Positive 2.5 0.11 0.1 0.9
*only variables with p value < 0.10 in the univariate analysis were included in the multivariate modelBMC Cancer 2009, 9:221 http://www.biomedcentral.com/1471-2407/9/221
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of CD133 immunoreaction has not to be underestimated:
with the limits inherent in the small series of cases with
positive CD133 staining, we reported that cases with api-
cal cytoplasmic CD133 expression showed a trend to a bet-
ter prognosis compared to cases with diffuse cytoplasmic
pattern of immunoreaction. At present, it is unknown
whether the subcellular localization of CD133 glycopro-
tein may affect CD133 function, or its involvement in can-
cer stem biology, although it has been hypothesized that
the apical/endoluminal staining represents a particular
step in cellular differentiation, while the less frequently
represented cytoplasmic staining would more likely char-
acterize cells with stemness features [24]. Our findings,
therefore, deserve to be further investigated in a larger
series.
Conclusion
In conclusion, we showed that the immunohistochemical
assessment of CD133 glycoprotein expression seems not
to provide information of potential clinical value for pre-
diction of response to treatment or prognosis in ovarian
cancer patients. Uncovering the physiology, the potential
tissue specificity, and the role of subcellular localization
of CD133 is crucial for determining the true role of this
antigen as a prognostic marker of CSCs in this neoplasia.
This issue becomes even more relevant considering that
attempts to target CSCs population are actively ongoing,
and a chimeric molecule combining the murine anti-
human CD133 and the cytotoxic drug monomethyl
auristatin has been already shown to be able to inhibit the
growth of gastric and hepatocellular cancer cells in vitro
and in vivo [34].
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